AU2014311558B2 - Compositions and methods for the treatment of presbyopia - Google Patents

Compositions and methods for the treatment of presbyopia Download PDF

Info

Publication number
AU2014311558B2
AU2014311558B2 AU2014311558A AU2014311558A AU2014311558B2 AU 2014311558 B2 AU2014311558 B2 AU 2014311558B2 AU 2014311558 A AU2014311558 A AU 2014311558A AU 2014311558 A AU2014311558 A AU 2014311558A AU 2014311558 B2 AU2014311558 B2 AU 2014311558B2
Authority
AU
Australia
Prior art keywords
concentration
aceclidine
present
tropicamide
vision
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014311558A
Other languages
English (en)
Other versions
AU2014311558A1 (en
Inventor
Gerald Horn
Lee NORDAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Presbyopia Therapies Inc
Original Assignee
Presbyopia Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Presbyopia Therapies Inc filed Critical Presbyopia Therapies Inc
Publication of AU2014311558A1 publication Critical patent/AU2014311558A1/en
Application granted granted Critical
Publication of AU2014311558B2 publication Critical patent/AU2014311558B2/en
Priority to AU2019200623A priority Critical patent/AU2019200623B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cosmetics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2014311558A 2013-08-28 2014-08-22 Compositions and methods for the treatment of presbyopia Ceased AU2014311558B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019200623A AU2019200623B2 (en) 2013-08-28 2019-01-31 Compositions and methods for the treatment of presbyopia

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201361871215P 2013-08-28 2013-08-28
US61/871,215 2013-08-28
US201361882998P 2013-09-26 2013-09-26
US61/882,998 2013-09-26
US201361904510P 2013-11-15 2013-11-15
US61/904,510 2013-11-15
US201361917620P 2013-12-18 2013-12-18
US61/917,620 2013-12-18
US201461938438P 2014-02-11 2014-02-11
US61/938,438 2014-02-11
PCT/US2014/052256 WO2015031186A1 (en) 2013-08-28 2014-08-22 Compositions and methods for the treatment of presbyopia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019200623A Division AU2019200623B2 (en) 2013-08-28 2019-01-31 Compositions and methods for the treatment of presbyopia

Publications (2)

Publication Number Publication Date
AU2014311558A1 AU2014311558A1 (en) 2016-03-17
AU2014311558B2 true AU2014311558B2 (en) 2019-01-24

Family

ID=52584080

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014311558A Ceased AU2014311558B2 (en) 2013-08-28 2014-08-22 Compositions and methods for the treatment of presbyopia
AU2019200623A Active AU2019200623B2 (en) 2013-08-28 2019-01-31 Compositions and methods for the treatment of presbyopia

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019200623A Active AU2019200623B2 (en) 2013-08-28 2019-01-31 Compositions and methods for the treatment of presbyopia

Country Status (22)

Country Link
US (1) US9089562B2 (https=)
EP (3) EP3542798B1 (https=)
JP (6) JP6426743B2 (https=)
KR (4) KR20160045147A (https=)
CN (1) CN105792815B (https=)
AU (2) AU2014311558B2 (https=)
CA (1) CA2922802C (https=)
DK (1) DK3542798T3 (https=)
ES (1) ES3028364T3 (https=)
FI (1) FI3542798T3 (https=)
HK (1) HK1225654A1 (https=)
HR (1) HRP20250507T1 (https=)
HU (1) HUE071646T2 (https=)
LT (1) LT3542798T (https=)
MX (2) MX393360B (https=)
PL (1) PL3542798T3 (https=)
PT (1) PT3542798T (https=)
RS (1) RS66821B1 (https=)
SG (1) SG11201601412XA (https=)
SI (1) SI3542798T1 (https=)
SM (1) SMT202500311T1 (https=)
WO (1) WO2015031186A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA113525C2 (xx) 2011-09-20 2017-02-10 Спосіб лікування пресбіопії
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
CN106455567A (zh) * 2013-12-18 2017-02-22 Gnt有限责任公司 用于治疗青光眼的组合物和方法
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
EP3302426A4 (en) 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
WO2016205071A1 (en) * 2015-06-18 2016-12-22 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
KR20180014825A (ko) * 2015-06-18 2018-02-09 프레스바이오피아 세라피스, 엘엘씨 눈의 굴절 이상 치료 및 원거리 시력 개선용 조성물 및 방법
CN106526888B (zh) * 2015-09-15 2019-08-06 星欧光学股份有限公司 隐形眼镜产品
US10845622B2 (en) 2015-09-15 2020-11-24 Largan Medical Co., Ltd. Multifocal contact lens and contact lens product
US12298602B2 (en) 2015-09-15 2025-05-13 Largan Medical Co., Ltd. Multifocal contact lens and contact lens product
PT3500255T (pt) * 2016-08-19 2023-01-10 Orasis Pharmaceuticals Ltd Composições farmacêuticas oftálmicas e utilizações relacionadas com estas
IT201700069664A1 (it) * 2017-06-22 2018-12-22 For Health Pharma S R L Nuova formulazione oftalmica a base di tropicamide
JP7170436B2 (ja) * 2017-06-28 2022-11-14 千寿製薬株式会社 水溶性高分子を含む点眼剤
CA3070556A1 (en) * 2017-07-20 2019-01-24 Alan Laboratories, Inc. Compositions and methods for treatment of myopia
JP6603785B2 (ja) * 2017-12-08 2019-11-06 千寿製薬株式会社 水溶性高分子を含む水性液剤
PL3681500T3 (pl) 2018-04-24 2022-08-01 Allergan, Inc. Zastosowanie chlorowodorku pilokarpiny w leczeniu starczowzroczności
TW202021584A (zh) * 2018-08-21 2020-06-16 美商歐樂根公司 α2 腎上腺素受體促效劑用於改善視力之用途
JP2020033290A (ja) * 2018-08-29 2020-03-05 興和株式会社 水性組成物
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
US10836760B2 (en) 2018-10-10 2020-11-17 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
WO2020252057A1 (en) * 2019-06-10 2020-12-17 Visus Therapeutics, Inc. Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality
CN114502155A (zh) * 2019-06-10 2022-05-13 视觉治疗股份有限公司 增强抗老视作用的卡巴胆碱-溴莫尼定制剂
CA3147107A1 (en) * 2019-07-26 2021-02-04 Allergan, Inc. Compositions and methods for treatment of presbyopia
WO2021236671A1 (en) * 2020-05-18 2021-11-25 Vyluma Inc. Low-dose carbachol compositions and methods for treatment of night vision disturbance
US20230190738A1 (en) * 2021-12-16 2023-06-22 Lenz Therapeutics, Inc. Compositions and methods for the treatment of eye conditions
PL4312986T3 (pl) * 2021-04-01 2025-02-17 Active Biotech Ab Preparat lakwinimodu do stosowania do oczu
WO2022232205A1 (en) * 2021-04-28 2022-11-03 Lenz Therapeutics, Inc. A method of reducing brow ache
KR102415950B1 (ko) 2021-07-13 2022-07-05 백두하 백국화 추출물, 모과 추출물 및 용안육 추출물의 혼합물을 유효성분으로 포함하는 눈 건강 기능 식품 및 이의 제조방법
TW202333662A (zh) * 2021-11-10 2023-09-01 美商偉視醫療股份有限公司 增強抗老花眼效果之卡巴可(carbachol)調配物
WO2023091439A1 (en) * 2021-11-17 2023-05-25 Lenz Therapeutics, Inc. Aceclidine derivatives, compositions thereof and methods of use thereof
US11648247B1 (en) 2021-12-16 2023-05-16 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia
CN114588156B (zh) * 2022-04-22 2024-06-11 温州医科大学附属眼视光医院 一种眼用制剂及其在治疗老花眼中的应用
KR102678138B1 (ko) * 2022-09-29 2024-06-25 주식회사태준제약 브리모니딘을 포함하는 안과용 조성물
KR20240099055A (ko) * 2022-12-21 2024-06-28 주식회사 대웅테라퓨틱스 이나보글리플로진을 포함하는 점안제 형태의 약학 조성물
WO2024220441A1 (en) * 2023-04-17 2024-10-24 Lenz Therapeutics Operations, Inc. Methods for the treatment of presbyopia
CN119789854A (zh) * 2023-08-04 2025-04-08 Ads医疗有限责任公司 用于递送眼科活性物的组合物和方法
CN119700989A (zh) * 2023-09-28 2025-03-28 苏州普乐康医药科技有限公司 一种α-肾上腺素受体激动剂眼用组合物及其用途
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia
WO2025259674A1 (en) * 2024-06-11 2025-12-18 Ads Therapeutics Llc Compositions and methods for delivery of pharmaceutical actives

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106644A1 (en) * 2001-04-03 2004-06-03 Alessandro Randazzo Composition for treatment of night sight problems(halos, comas and glare) after refractive surgery, intra ocular lens implant after lensectomy or intraocular implant in phakic patients comprising aceclidine employed at low concentrations
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
CA2031469A1 (en) * 1989-12-28 1991-06-29 Larry A. Wheeler Use of inclusion complexes of prostaglandins with cyclodextrins in the treatment of ocular hypertension
US5073560A (en) * 1990-07-20 1991-12-17 Fisons Corporation Spiro-isoxazolidine derivatives as cholinergic agents
US6291466B1 (en) * 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
AR034371A1 (es) 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
JP2003201241A (ja) 2001-10-22 2003-07-18 Rohto Pharmaceut Co Ltd 眼科用組成物
JP2004168709A (ja) * 2002-11-20 2004-06-17 Nidek Co Ltd 抗アレルギー点眼点鼻用組成物
US20060172972A1 (en) * 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
JP2008536866A (ja) 2005-04-15 2008-09-11 ボード、オブ、トラスティーズ、オブ、ミシガン、ステイト、ユニバーシティ アミン作動性医薬組成物および方法
ES2329161T3 (es) 2006-12-18 2009-11-23 Jorge Luis Benozzi Composiciones oftalmicas de estimulantes parasimpaticos y antiinflamatorios para su uso en el tratamiento de la presbicia.
EP2097044A4 (en) * 2006-12-26 2012-10-10 Quadra Logic Tech Inc DRUG RELIEF IMPLANTS FOR INHIBITING OPTICAL DEFECTS
GB0724558D0 (en) 2007-12-15 2008-01-30 Sharma Anant Optical correction
US20110212142A1 (en) * 2008-11-17 2011-09-01 Laila Pharmaceuticals Pvt.Ltd. Curcuminoids and its metabolites for the application in ocular diseases
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
WO2010125416A1 (en) * 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
WO2010135731A1 (en) 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
AU2009347921B8 (en) 2009-06-10 2014-07-24 Mitotech Sa Pharmaceutical composition for use in medical and veterinary ophthalmology
WO2011011519A1 (en) * 2009-07-21 2011-01-27 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
JP2013523825A (ja) * 2010-04-07 2013-06-17 アラーガン インコーポレイテッド 眼科製剤のための保存剤組成物の組み合わせ
WO2011127151A2 (en) * 2010-04-07 2011-10-13 Allergan, Inc. Combinations of preservatives for ophthalmic compositions
JP2014506936A (ja) 2011-03-03 2014-03-20 アラーガン インコーポレイテッド シリコーンベースの眼科製剤
UA113525C2 (xx) 2011-09-20 2017-02-10 Спосіб лікування пресбіопії
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106644A1 (en) * 2001-04-03 2004-06-03 Alessandro Randazzo Composition for treatment of night sight problems(halos, comas and glare) after refractive surgery, intra ocular lens implant after lensectomy or intraocular implant in phakic patients comprising aceclidine employed at low concentrations
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer

Also Published As

Publication number Publication date
CA2922802A1 (en) 2015-03-05
ES3028364T3 (en) 2025-06-19
EP3542798B1 (en) 2025-03-19
PT3542798T (pt) 2025-05-20
AU2019200623B2 (en) 2019-10-03
LT3542798T (lt) 2025-06-10
KR20220129097A (ko) 2022-09-22
AU2019200623A1 (en) 2019-02-21
SG11201601412XA (en) 2016-03-30
JP2021183634A (ja) 2021-12-02
WO2015031186A1 (en) 2015-03-05
EP3038610A1 (en) 2016-07-06
AU2014311558A1 (en) 2016-03-17
JP7358221B2 (ja) 2023-10-10
KR20160045147A (ko) 2016-04-26
JP2025131705A (ja) 2025-09-09
EP4563162A3 (en) 2025-08-20
JP7329019B2 (ja) 2023-08-17
US20150065511A1 (en) 2015-03-05
CA2922802C (en) 2021-04-27
MX393360B (es) 2025-03-24
MX2020002922A (es) 2020-07-22
RS66821B1 (sr) 2025-06-30
HUE071646T2 (hu) 2025-09-28
MX2016002623A (es) 2016-09-23
JP2016529297A (ja) 2016-09-23
KR20260008183A (ko) 2026-01-15
HRP20250507T1 (hr) 2025-06-20
KR20230157530A (ko) 2023-11-16
JP6426743B2 (ja) 2018-11-21
JP2019031538A (ja) 2019-02-28
PL3542798T3 (pl) 2025-09-08
SMT202500311T1 (it) 2025-09-12
HK1225654A1 (zh) 2017-09-15
US9089562B2 (en) 2015-07-28
KR102905081B1 (ko) 2025-12-26
CN105792815A (zh) 2016-07-20
EP3542798A1 (en) 2019-09-25
EP3038610A4 (en) 2017-03-22
DK3542798T3 (da) 2025-05-19
JP2023103400A (ja) 2023-07-26
KR102600484B1 (ko) 2023-11-09
JP2020055851A (ja) 2020-04-09
CN105792815B (zh) 2018-08-28
SI3542798T1 (sl) 2025-07-31
EP4563162A2 (en) 2025-06-04
FI3542798T3 (fi) 2025-05-21

Similar Documents

Publication Publication Date Title
AU2019200623B2 (en) Compositions and methods for the treatment of presbyopia
KR102598047B1 (ko) 눈의 굴절 이상 치료 방법 및 저장 안정성 조성물
US9320709B2 (en) Storage stable compositions and methods for the treatment of refractive errors of the eye
US10064818B2 (en) Compositions and methods for the treatment of presbyopia
US9314427B2 (en) Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
US9833441B2 (en) Compositions and methods for the treatment of presbyopia
US20160193193A1 (en) Compositions and Methods for the Treatment of Presbyopia
WO2016205071A1 (en) Compositions and methods for the treatment of presbyopia
HK40111435A (en) Storage stable compositions and methods for the treatment of refractive errors of the eye
HK40014460A (en) Aceclidine for use in the treatment of presbyopia
HK40014460B (en) Aceclidine for use in the treatment of presbyopia

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired